Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Gilead Sciences’ stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...